This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma ba...
- Carcinoma
- Adenocarcinoma
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Carcinoma, Transitional Cell
- Uterine Neoplasms
- Endometrial Neoplasms
Age: 18 years - 66+
Gender: All